Factorial study of the efficacy of cholestyramine, L-tryptophan and clofibrate in human nephrotic hyperlipidaemia.
作者信息
Schapel G J, Edwards K D, Neale F C
出版信息
Prog Biochem Pharmacol. 1974;9:82-98.
PMID:4438384
Abstract
摘要
相似文献
1
Factorial study of the efficacy of cholestyramine, L-tryptophan and clofibrate in human nephrotic hyperlipidaemia.消胆胺、L-色氨酸和氯贝丁酯治疗人类肾病性高脂血症疗效的析因研究。
Prog Biochem Pharmacol. 1974;9:82-98.
2
Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia.氧雄龙、卤芬酯和氯贝丁酯在实验性急性肾病性高脂血症析因研究中的疗效及相互作用
J Pharmacol Exp Ther. 1975 Jul;194(1):274-84.
3
Clofibrate-induced muscle damage in patients with chronic renal failure.氯贝丁酯诱导的慢性肾衰竭患者肌肉损伤
Lancet. 1975 Dec 27;2(7948):1279-82. doi: 10.1016/s0140-6736(75)90613-3.
4
Antilipaemic drugs and nephrotic hyperlipidaemia.抗脂药物与肾病性高脂血症
Prog Biochem Pharmacol. 1972;7:370-426.
5
[Dyslipidemia in the nephrotic syndrome. Physiopathological aspects and therapeutic prospects].
Minerva Nefrol. 1975 Nov-Dec;22(6):243-51.
6
[Therapy of hyperlipidemias].
Wien Klin Wochenschr. 1971 Oct 1;83(39):691-4.
7
Hyperlipidemia: reducing the chances of cardiovascular disease.
Geriatrics. 1984 Jul;39(7):99-100, 103-4,108-9 passim.
8
The efficacy of lipid lowering drugs alone and in combination.
Postgrad Med J. 1975;51(8):63-5.
9
[Clinical trials of cholestyramine alone and in combination with clofibrate in hypercholesterolemia].
Lakartidningen. 1974 Sep 4;71(36):3289-91.
10
Treatment of essential hyperlipidaemia.
Lancet. 1970 Jan 24;1(7639):191-2. doi: 10.1016/s0140-6736(70)90430-7.
Zotero 插件